<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2981059/" ref="ordinalpos=4782&amp;ncbi_uid=3331033&amp;link_uid=PMC2981059" image-link="/pmc/articles/PMC2981059/figure/fig6/" class="imagepopup">Fig. 6. From: Secretory phospholipase A2-IIa is involved in prostate cancer progression and may potentially serve as a biomarker for prostate cancer. </a></div><br /><div class="p4l_captionBody">The HER/HER2-PI3K-Akt-NF-κB-elicited pathway in prostate cancer cells. PI3K-Akt signaling cross talks with the NF-κB-mediated pathway by Akt phosphorylation and activation of IKK, an upstream kinase of NF-κB. Small molecule inhibitors Erlotinib, Gefitinib, Lapatinib, CI-1033, LY294002, Bortezomib, cFLSYR and c(2NapA)LS(2NapA)R against EGFR, HER2, PI3K, NF-κB and sPLA2 are indicated.</div></div>